Compare IBKR & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IBKR | BIIB |
|---|---|---|
| Founded | 1977 | 1978 |
| Country | United States | United States |
| Employees | 2998 | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.7B | 34.5B |
| IPO Year | 2006 | 1996 |
| Metric | IBKR | BIIB |
|---|---|---|
| Price | $71.64 | $250.64 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 36 |
| Target Price | $104.04 | ★ $268.26 |
| AVG Volume (30 Days) | ★ 4.6M | 1.1M |
| Earning Date | 10-15-2026 | 10-28-2026 |
| Dividend Yield | ★ 0.79% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 1.98 | ★ 2.66 |
| Revenue | $2,580,000,000.00 | ★ $9,890,600,000.00 |
| Revenue This Year | $19.72 | $7.00 |
| Revenue Next Year | $19.70 | $1.82 |
| P/E Ratio | ★ $38.21 | $92.96 |
| Revenue Growth | ★ 9.04 | 2.22 |
| 52 Week Low | $61.03 | $160.36 |
| 52 Week High | $98.75 | $261.00 |
| Indicator | IBKR | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 34.73 | 54.94 |
| Support Level | $63.51 | $240.00 |
| Resistance Level | $91.31 | $259.89 |
| Average True Range (ATR) | 3.19 | 7.20 |
| MACD | -0.22 | -1.24 |
| Stochastic Oscillator | 4.92 | 50.24 |
Interactive Brokers is a large, automated retail and institutional brokerage that boasted nearly $780 billion in customer equity at the end of 2025. The company cut its teeth as a market maker, introducing US financial markets to automated and algorithmic training before expanding into brokerage services in 1993. The firm has a wide-ranging client base, with its best-in-class order execution and extremely low margin lending rates catering to a sophisticated audience of hedge funds, proprietary traders, and introducing brokers that account for about 45% of the firm's commissions. With operations spanning more than 170 electronic exchanges, 40 countries, and 29 currencies, Interactive Brokers caters to a global clientele, with more than 80% of client accounts sitting outside the US.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).